相关实验视频

Updated: Jun 22, 2025

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

歇斯脱乙酶抑制减轻了由粉样β (Aβ) 寡合体诱导的认知缺陷和星球细胞功能障碍

Luan Pereira Diniz¹, Juliana Morgado¹, Ana Paula Bergamo Araujo¹

¹Laboratório de Neurobiologia Celular, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

British journal of pharmacology

|June 27, 2024

概括

新的药物LASSBio-1911,素脱乙酶 (iHDACs) 抑制剂,通过保护星球细胞和改善小鼠模型中的认知和突触功能,显示出对阿尔茨海默病 (AD) 的治疗潜力.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
细胞生物学细胞生物学

背景情况:

激素脱乙酶抑制剂 (iHDACs) 正在成为神经退行性疾病的潜在治疗方法.
星球细胞在神经炎症和阿尔茨海默病 (AD) 发病过程中发挥着至关重要的作用.
粉样β oligomers (AβOs) 是AD病理和神经毒性的关键贡献者.

研究的目的:

为了评估新型iHDAC的治疗潜力,LASSBio-1911.
研究LASSBio-1911对天体细胞功能和表型的影响.
评估LASSBio-1911对AβO毒性模型和AD认知功能的影响.

主要方法:

在体外和体内研究使用星细胞培养和AβO输液的小鼠模型.
通过流式细胞计量,西式涂抹,免疫光和qPCR评估天体细胞表型和突触密度.
使用行为测试评估认知功能.

主要成果:

LASSBio-1911在体外和体内调节了天体细胞的反应性和协同产生的潜力.
该化合物增强了星球细胞的神经保护能力,并改善了突触标记物.
在AβO注入的小鼠中,LASSBio-1911的管理挽救了突触和记忆缺陷,改善了行为表现.

结论:

LASSBio-1911显示出对阿尔茨海默病的显著治疗潜力.
这项研究强调了星球细胞在阿尔茨海默病中的关键作用,并建议它们作为可行的治疗点.
针对像LASSBio-1911这样的iHDACs的星细胞提供了AD治疗的有希望的策略.

关键词:

阿尔茨海默病的疾病阿尔茨海默病的疾病.星球细胞是星球细胞.基因素脱乙酶抑制剂基因素脱乙酶抑制剂多重目标药物多重目标药物神经炎症是一种神经炎症.反应性反应性是指反应性.

更多相关视频

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.